Author: Kathir J

Base58 Labs Advances Integration of Proprietary BHLE Infrastructure

LONDON, United Kingdom – 04/03/2026 – (SeaPRwire) – BASIS has announced a significant acceleration in platform development following its recent $35 million Pre-Series A capital raise. The funding enables parent company Base58 Labs to advance the commercial integration of its proprietary Base58 Hyper-Latency Engine (BHLE) into the BASIS staking infrastructure.

BHLE, developed over multiple years within institutional high-frequency trading (HFT) research environments, is now transitioning from research phase into structured platform deployment. The engine is designed to enhance execution efficiency, reduce latency-related inefficiencies, and optimise liquidity management across fragmented digital asset markets.

Industry observers note that the integration of institutional-grade execution frameworks into a staking infrastructure model represents a strategic evolution within the broader digital asset ecosystem. While detailed technical specifications remain confidential, Base58 Labs confirmed that BHLE will serve as a core execution layer within the BASIS architecture.

In parallel with the technical acceleration, Base58 Labs has initiated a large-scale recruitment programme across Europe and the United Kingdom. The company is onboarding quantitative engineers, blockchain systems architects, and regulatory compliance specialists, all of whom will focus exclusively on BASIS platform development and infrastructure scaling.

“Our objective is to combine years of proprietary research with expanded operational capacity,” a company spokesperson stated. “The recent capital raise enables us to consolidate technical, intellectual, and human resources around a single mission: delivering a high-performance staking infrastructure aligned with institutional standards.”

BASIS is also being developed with regulatory alignment in mind, including adherence to emerging European frameworks such as MiCA (Markets in Crypto-Assets). The platform aims to provide a structurally robust environment for both institutional and retail participants.

With liquidity reserves strengthened and integration milestones progressing, BASIS remains on track for an official launch in the second half of 2026.

About Base58 Labs

Base58 Labs is a London-based digital infrastructure company specialising in high-performance execution technologies and blockchain optimisation systems. Learn more: https://base58labs.com/

Media Contact

Base58 Labs PR Team

Email: info@base58labs.com

BASIS Official Website: https://basis.pro/

Base58 Labs Official Website: https://base58labs.com/

 

Hong Kong – 02/03/2026 – (SeaPRwire) – At the India AI Impact Summit 2026, AI Safety Asia (AISA) convened two important conversations on the future of AI governance. The first examined how governments should respond when AI-related crises unfold across borders at machine speed. The second marking the launch of the International AI Safety Report 2026.

Taken together, these sessions showed a change in the debate; moving past whether AI should be governed to a focus on how.

Who verifies claims made by powerful systems? Who coordinates when an incident crosses jurisdictions in seconds? Who is responsible when an autonomous system acts, and no single ministry appears in charge? As AI systems become more agentic and embedded deeper into critical infrastructure, they are forcing diplomatic and regulatory institutions to respond in real time. The pressure on diplomatic and regulatory institutions is no longer just a theory, it is operational.

Governing AI in a Fragmented World

On 17 February at Bharat Mandapam, AISA co-hosted the session “AI Crisis Diplomacy: Governing AI in a Fragmented World” in partnership with the Center for Human-Compatible AI (CHAI) and the International Association for Safe and Ethical Artificial Intelligence (IASEAI).

The session brought together senior experts in the space; Professor Stuart Russell, Audrey Tang, Dr. Yuko Harayama, Wan Sie Lee, and Azizjon Azimi, moderated by AISA’s Chief Strategy Officer, Adjunct Professor Alejandro Reyes.

Rather than rehearse abstract debates about regulation, the discussion focused on plausible crisis scenarios: a cross-border deepfake incident that destabilises diplomatic relations before verification catches up; an AI-enabled cyberattack cascading across jurisdictions; an autonomous infrastructure system operating in one country, hosted in another, and affecting a third.

The problem is not only detection. It is coordination under uncertainty.

The familiar argument that AI evolves too quickly to regulate was put under scrutiny. The pace of innovation does not make governance obsolete. Aviation, nuclear energy, and pharmaceuticals are governed by setting acceptable risk thresholds and requiring evidence that systems meet them. AI should be treated no differently. Governments need to insist on demonstrable safety and credible liability frameworks, rather than accepting disclaimers and opaque risk claims.

Governments already know how to cooperate during crises. Pandemic response and cybersecurity have shown that cross-border coordination is possible. The gap in AI governance is not diplomatic architecture in principle, but operational channels between those responsible for technical evaluation. Joint testing efforts are not only about measuring model performance. They build trust, and trust is what allows regulators to pick up the phone, compare signals, and verify before escalation spirals.

AI does not create entirely new categories of crisis, but amplifies existing ones. What changes is speed and scale. Human institutions deliberate; AI systems act, and bridging that gap requires new protocols, shared verification standards, and regular engagement long before a crisis forces coordination under pressure.

Governance capacity matters, and durable infrastructure outperforms isolated interventions. Crisis diplomacy cannot be improvised, it must be built through trusted networks, regionally grounded expertise, and repeat engagement.

The Evidence Dilemma and the 2026 International AI Safety Report

On 18 February, AISA co-hosted the International AI Safety Report 2026 Launch Reception at the High Commission of Canada in India, in partnership with the High Commission, the UK AI Security Institute, and Mila – Quebec Artificial Intelligence Institute.

The event featured Professor Yoshua Bengio, Chair of the Report and Founder and Scientific Advisor of Mila, supported by co-leads Carina Prunkl and Stephen Clare.

The report provides an independent scientific assessment of frontier general-purpose AI capabilities and risks; focusing on emerging risks, including malicious use, autonomous malfunctions, and systemic disruption, and confronts the evidence dilemma. Policymakers must act under conditions of uncertainty, yet waiting for perfect data runs the risk of leaving societies exposed.

The Report documents rapid advances in reasoning systems and AI agents, as well as continued reliability challenges, risks in cyber and bio domains, and growing systemic concern; underscoring that risk management cannot rely on a single safeguard. Technical measures, institutional oversight, and societal resilience must be layered.

The choice is not between innovation and safety, it is between unmanaged acceleration and accountable progress. Evidence standards, robust evaluations, and credible thresholds are essential if public trust is to keep pace with technical capability.

For countries across Asia and the broader Global South, the issue is how to shape governance frameworks that reflect local institutional realities while contributing to global norms. AISA’s mission is to ensure that regional expertise informs both national decisions and international debates.

From Conversation to Capacity

AI governance is not a single regulatory instrument. It is an evolving institutional practice. The next phase will be defined less by declarations and more by whether governments can verify claims, share information at speed, and operationalise coordination before crises escalate.

Asia is not waiting for governance models to arrive from elsewhere. Across the region, policymakers, regulators, and technical experts are building their own capacity to govern frontier technologies responsibly, shaped by local realities and regional priorities. The next AI-driven crisis will not unfold on a diplomatic timetable; it will move at machine speed. Whether diplomacy and safety can keep up will depend on the institutions, relationships, and verification channels being built now, not after the fact.

About AI Safety Asia

AI Safety Asia (AISA) believes progress in AI must begin with people. Since 2024, AISA has engaged more than 2,000 AI governance professionals across 16 Asian countries. Its work centres on building durable governance infrastructure: research that is regionally grounded, structured peer learning, and implementation-oriented engagement.

AISA helps build capacity, bringing together policymakers, experts, and civil society to strengthen the knowledge, networks, and trust required to govern frontier technologies responsibly, grounded in regional realities. The institutions and relationships built today will determine whether diplomacy and safety can keep up.

Social Link

LinkedIn: https://www.linkedin.com/company/ai-safety-asia/

Media Contact

Brand: AI Safety Asia

Contact: Media team

Email: contact@aisafety.asia

Website: https://www.aisafety.asia

As 2026 marks the beginning of China’s 15th Five-Year Plan (2026–2030) amid rising global volatility and fragmentation, CGTN published an analysis exploring how China will sustain steady economic growth, and what drives the resilience of the world’s second-largest economy.

Despite mounting external headwinds, China’s economy has demonstrated “remarkable resilience,” Marshall Mills, IMF’s senior resident representative to China, said late 2025. Noting that China contributes around 30 percent to global growth, he said the country’s steady outlook provides significant support to the world economy at a time of heightened uncertainty.

As 2026 opens the first year of China’s 15th Five-Year Plan (2026–2030), policymakers have laid out a clear roadmap. At the Central Economic Work Conference at the end of 2025, Chinese President Xi Jinping set the overall tone for this year’s economic policy as “pursuing progress while maintaining stability, and improving quality and efficiency.”

“There are many tasks on the economic agenda for 2026. We must grasp the key points and ensure coordinated progress,” Xi said.

In a world marked by volatility and fragmentation, China’s strategy centers on deepening structural reform, strengthening the business environment and accelerating technological innovation.

Stable policies underpin economic growth

China’s top-level policy framework provides a strong institutional foundation for innovation-driven development. This stability and predictability not only supports domestic growth but also reduces uncertainty for businesses and strengthens market confidence.

Over the years, China has elevated scientific and technological self-reliance to a strategic priority and set the goal of building a global science and technology powerhouse by 2035.

This vision has been backed by concrete policy measures. Authorities have advanced major national science projects and laboratories, positioned enterprises as the primary drivers of innovation, strengthened collaboration among industry, universities and research institutes, and improved support mechanisms through tax incentives, R&D subsidies, talent programs and science-and-technology finance initiatives.

At the same time, efforts to improve the business environment and invigorate the private sector have continued. Measures include expanded financing channels, tax and fee cuts, relaxed market access and stronger legal protection.

In January last year, the country’s top economic planner, the National Development and Reform Commission (NDRC), released guidelines for building a unified national market to reduce transaction costs and improve factor mobility nationwide.

Meanwhile, China’s national lawmakers last April passed the country’s first fundamental law dedicated to promoting the private sector, seeking to ensure fair competition, improve financing access and strengthen legal protections for private enterprises. China has also fully removed foreign investment access restrictions in the manufacturing sector and further shortened its negative list for foreign investment.

For the 15th Five-Year Plan period, building a modern industrial system, fostering new quality productive forces, expanding domestic demand and advancing higher-level opening-up have been placed at the forefront.

Strong foundations, vast potential

Recent data underscores the effectiveness of this policy framework. In 2025, China’s GDP reached 140.19 trillion yuan (about $20.13 trillion), up 5 percent year on year, while foreign trade totaled 45.47 trillion yuan, marking nine consecutive years of growth.

Liu Shangxi, vice chairman of the China Macroeconomics Society, said the performance reflects Chinese economy’s internal resilience despite external disruptions.

Beyond headline figures, structural upgrading has accelerated. Traditional industries have stepped up digital and green transformation, while strategic emerging sectors – including next-generation information technology, high-end equipment manufacturing and new energy vehicles – have expanded rapidly.

Green transition has become a defining feature of this shift. In 2025, China’s new energy vehicle output exceeded 16 million units, maintaining its global lead for the 11th consecutive year. The country has also built the world’s largest and most comprehensive renewable energy industrial chain. Energy consumption per unit of GDP has fallen 11.6 percent compared with 2020, equivalent to cutting roughly 1.1 billion tonnes of carbon dioxide emissions.

Meanwhile, technological innovation is increasingly embedded across industrial chains. Taking AI as an example, official data shows that by early 2026, China had more than 6,000 artificial intelligence companies, with the core AI industry surpassing 1.2 trillion yuan in scale – up nearly 30 percent year on year. Domestic open-source large models have recorded over 10 billion cumulative global downloads, signaling widespread industrial integration.

With its vast domestic market, complete industrial system, deep talent pool and strengths in digital and green sectors, China has built a comprehensive competitive edge, Liu noted. These fundamentals, he said, will not only sustain the world’s second-largest economy, but also inject greater predictability and stability into an increasingly uncertain global landscape.

https://news.cgtn.com/news/2026-02-28/30-global-growth-drive-China-s-15th-FYP-kicks-off-with-confidence-1L83YGIBh8Q/p.html

Hangzhou, China – Recently, Geely RIDDARA officially launched the RD6 PHEV in Costa Rica, marking the brand’s third model in the market following the RD6 and RD6 Econ. With three products now available locally, Geely RIDDARA has reinforced its leading position in Costa Rica’s new energy pickup segment.

The Costa Rica launch marks another step in Geely RIDDARA’s accelerating expansion across Latin America, building a presence across multiple markets and usage scenarios. In Chile, the RD6 has performed strongly in high-intensity applications such as mining since entering the market in 2024. The introduction of the RD6 PHEV in December 2025 further strengthened the brand’s competitiveness among commercial customers.

In Uruguay, the RD6 has steadily gained traction with individual users since its 2024 launch, supported by the rollout of the RD6 Econ in August 2025, which continues to drive market share growth. Panama, Colombia, and Bolivia also completed product introductions during 2025, marking broader regional expansion.

As its Latin America footprint continues to grow, Geely RIDDARA is advancing its global presence in parallel. To date, the brand has entered more than 60 countries and regions across Latin America, Asia-Pacific, the Middle East, Africa, and Europe. Its global lineup now comprises three core models — RD6, RD6 Econ, and RD6 PHEV — covering both pure electric and plug-in hybrid powertrains.

This global expansion is underpinned by Geely RIDDARA’s established new energy technology base. Backed by Geely Group’s R&D capabilities, the brand has developed China’s first native electric pickup platform and introduced EM-P hybrid technology into the pickup segment. These innovations enable scalable, market-ready new energy solutions worldwide.

Designed around the concept “Function like a Pickup, Drive like an SUV,” the RD6 PHEV combines strong performance with everyday usability. It accelerates from 0 to 100 km/h in 6.3 seconds. Intelligent electric all-wheel drive and multiple terrain modes ensure confident handling in demanding road conditions. With a rated payload of 875 kg and a towing capacity of 2.5 tons, the model supports agricultural, mining, and logistics operations. A combined driving range of over 1,000 km and vehicle-to-load capability further enhance efficiency in daily and commercial use.

Alongside its overseas expansion, Geely RIDDARA continues to lead China’s new energy pickup market. Sales data released in January 2025 show the brand achieved a 52.2% market share in the new energy pickup segment and an 82.8% share in the pure electric pickup segment, ranking first for three consecutive years (source: CATARC). Building on this foundation, Geely RIDDARA is accelerating the global rollout of its technologies and products, reinforcing its commitment to delivering efficient and reliable new energy pickup solutions worldwide.

 

About KEN WILL

 

KEN WILL is a globally recognized singer, songwriter, and producer known for blending contemporary R&B; with modern pop sensibility. Signed to Warner Music Group in December 2025, he continues to shape his sound through releases that merge emotional authenticity with refined sonic craftsmanship.

 

KEN WILL Releases Single “Coffee” Release Date: February 27, 2026 Single Title: Coffee

Label: Warner Music Group (WMG)

 

About KEN WILL

 

KEN WILL is a globally recognized singer, songwriter, and producer known for blending contemporary R&B; with modern pop sensibility. Signed to Warner Music Group in December 2025, he continues to shape his sound through releases that merge emotional authenticity with refined sonic craftsmanship.

 

KEN WILL Releases Single “Coffee” Release Date: February 27, 2026 Single Title: Coffee

Label: Warner Music Group (WMG)

SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received the acceptance from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of mild to moderate atopic dermatitis on 24 February 2026. The Product is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The NDA has been approved for inclusion in the Priority Review List by the Center for Drug Evaluation (CDE) of the NMPA based on its qualification as a “new variety, dosage form and specification of pediatric drug that conforms to the physiological characteristics of children”, which is expected to accelerate the Product’s review process for marketing approval in the AD indication.

 

Impressive phase III trial data in AD

Its Priority Review is expected to accelerate its NDA approval

 

Ruxolitinib phosphate cream was approved for marketing by the NMPA in January 2026, becoming the first and only targeted drug approved in China for the treatment of vitiligo. The acceptance of this NDA for the additional indication of AD marks a key milestone in the Product’s expansion into multiple therapeutic areas.

 

Ruxolitinib phosphate cream has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical trial in China for mild to moderate AD.

50. Robust Efficacy: The Product successfully met its primary endpoint, demonstrating that a significantly higher proportion of subjects treated with ruxolitinib phosphate cream achieved IGA (Investigator’s Global Assessment) of 0 or 1 with at least two grades of reduction from baseline at week 8, compared with placebo (63.0% vs 9.2%, P < 0.001). For the key secondary endpoint, the proportion of subjects achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index score (EASI 75) of treatment with ruxolitinib phosphate cream was also significantly higher than that of the placebo group, at week 8 (78.0% vs 15.4%, P < 0.001).
50. Favorable Safety Profile: The severity of treatment-emergent adverse events (TEAE) during the treatment period was mostly mild or moderate, with no TEAEs leading to discontinuation of the study drug. Overall, ruxolitinib phosphate cream was safe and well-tolerated.

 

Furthermore, the NDA has been approved for inclusion in the Priority Review List. According to relevant NMPA regulations, the review timeline for marketing applications subject to Priority Review and Approval Procedure is substantially shortened—from the standard 200 days to 130 days. This significant reduction in the review timeline is expected to accelerate the marketing process of ruxolitinib phosphate cream for the AD indication, benefiting a wide range of patients at an earlier date.

 

Building an integrated AD solution,

strengthening Dermavon’s leadership in dermatology

 

AD is a chronic, recurrent and inflammatory dermatologic disease, with the main clinical manifestations of dry skin, chronic eczema-like lesions and obvious itching or pruritus, which may seriously affect the quality of life of patients. It is estimated that there were over 54 million AD patients in China as of 2024. Based on SCORAD scores, mild to moderate AD accounts for 98% of these cases, representing over 52.5 million patients^[1]. Topical drugs are the most basic treatment for AD. Traditional topical medications such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) have clinical pain points with long-term adverse reactions or limited efficacy, therefore novel treatments are urgently needed.

 

Dermavon has developed a comprehensive “treatment + care” integrated solution for AD. In addition to the topical formulation ruxolitinib phosphate cream for mild-to-moderate AD, the portfolio also includes the injectable biological agent Comekibart Injection (MG-K10) for moderate-to-severe AD, the oral small molecule targeted drug CMS-D001 for moderate-to-severe AD, and the Heling Soothing Product Series for daily repair, to meet the management needs of AD patients from treatment to daily care.

 

Simultaneously, the acceptance of the NDA for the AD indication will strengthen Dermavon’s strategic layout in the field of skin treatments and create synergies with its commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon’s market competitiveness and brand influence in the field of skin health.

 

More Information About Ruxolitinib Phosphate Cream

Ruxolitinib phosphate cream (Opzelura^®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte. In China, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. In the U.S., ruxolitinib phosphate cream is the first topical JAK inhibitor approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of non-segmental vitiligo in patients aged 12 years and older, and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable^[2]. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age^[3].

 

The Group, through its subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary).

 

Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura^®. Opzelura^® and the Opzelura^® logo are registered trademarks of Incyte.

 

 

About CMS

 

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

 

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

 

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.

 

Reference:

1. China Insights Consultancy’s industrial report

2. The U.S. FDA approval information can be found on the Incyte official website, as follows:

https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib

3. The EMA approval information can be found on the Incyte official website, as follows:

https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar

 

 

CMS Disclaimer and Forward-Looking Statements

 

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

 

 

With strong momentum, expanding partnerships, and a clear strategic roadmap, the organization now looks ahead to building on this success and continuing its mission of driving innovation and community empowerment on a global scale.

February 4, 2026 — OHO SUNSHINE today announced an update in U.S. International Trade Commission (“ITC”) Section 337 Investigation No. 337-TA-1455.

According to public records, Complainant IngenioSpec, LLC filed a motion on December 1, 2025, to terminate the investigation as to Shenzhen Langzhiyin Electronic Co., Ltd. (doing business as OHO SUNSHINE) by withdrawing the complaint. On December 17, 2025, the presiding Administrative Law Judge issued Order No. 22, an Initial Determination granting the motion for termination as to OHO SUNSHINE.

 

The Initial Determination granted the request to stay deadlines in the procedural schedule as they relate to OHO pending Commission review. The Commission subsequently determined on January 16, 2026, not to review the Initial Determination, and the investigation is terminated as to OHO.

The investigation, as instituted, concerned allegations under Section 337 relating to certain electronic eyewear products and asserted patents, U.S. Patent Nos. 10,310,296 and 12,078,870.

Throughout the process, OHO SUNSHINE maintained full cooperation with the proceedings and worked closely with its U.S. counsel, Rimon, P.C., to protect its lawful rights and interests. The company consistently maintained that the allegations lacked merit and emphasized that its products are independently developed, supported by its own innovation and intellectual property portfolio.

Business operations, product deliveries, and customer support continue without interruption. Given the nature of legal proceedings, the company will not comment on non-public details. 

About OHO SUNSHINE

OHO SUNSHINE is a global smart eyewear brand created by Shenzhen Langzhiyin Electronic Co., Ltd., specializing in Bluetooth audio glasses, camera glasses, and AI translation eyewear. Originating from an OEM/ODM manufacturing background since 2009, the company has evolved into an independent global brand integrating advanced technology into stylish, everyday eyewear designs, serving customers worldwide with comprehensive shipping, warranty, and customer support.